This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $255.46 in the latest trading session, marking a +0.03% move from the prior day.
Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA
by Zacks Equity Research
Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $253.37 in the latest trading session, marking a +0.57% move from the prior day.
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen's (AMGN) Stelara Biosimilar Meets Psoriasis Study Goal
by Zacks Equity Research
Initial data from a late-stage study comparing Amgen's (AMGN) Stelara biosimilar candidate with the original Stelara drug showed no clinically meaningful differences in treating plaque psoriasis.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $253.51, marking a +1.39% move from the previous day.
BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study
by Zacks Equity Research
BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.
Amgen (AMGN) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $250.87, moving -0.46% from the previous trading session.
Esperion's (ESPR) Drug Sales and Cost-Cutting Drive Stock YTD
by Zacks Equity Research
Esperion's (ESPR) stock rallies so far this year on higher product sales in the fourth quarter of 2021. Cost-saving initiatives to boost margins in 2022 are another key drivers.
Amgen (AMGN) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $244.56, moving -0.13% from the previous trading session.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $244.87 in the latest trading session, marking a +0.72% move from the prior day.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $241.54, moving +0.44% from the previous trading session.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $240.47, moving +0.7% from the previous trading session.
Ligand (LGND) Inks Merger Deal With SPAC for OmniAb Spin-Off
by Zacks Equity Research
Ligand (LGND) is on track to spin-off its OmniAb business in the second half of 2022. It signs a merger agreement with a special purpose acquisition company (SPAC), Avista Public Acquisition Corp. for the same.
Are Options Traders Betting on a Big Move in Amgen (AMGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights Comcast, Danaher, Amgen, Boeing and Canadian Pacific Railway
by Zacks Equity Research
Comcast, Danaher, Amgen, Boeing and Canadian Pacific Railway have been included in this Analyst Blog.
Top Stock Reports for Comcast, Danaher & Amgen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Danaher Corporation (DHR), and Amgen Inc. (AMGN).
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $236.47, marking a +0.06% move from the previous day.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $236.32, moving +0.03% from the previous trading session.
Amgen (AMGN) Outperforms Industry This Year So Far: What Next?
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Sanofi (SNY), Blackstone Ink Deal for Subcutaneous Sarclisa
by Zacks Equity Research
Sanofi (SNY) is developing a subcutaneous formulation of its myeloma drug, Sarclisa. A pivotal study is expected to start in the second half of 2022.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $229.21 in the latest trading session, marking a +0.16% move from the prior day.